Table 2. Comparison with normal controls before GnRH agonist treatment and after discontinuation of treatment.
| Parameters | Before treatment | 6 months after discontinuation | ||||
|---|---|---|---|---|---|---|
| CPP group A (n = 98) | Control group 1 (n = 55) | P value | CPP group E (n = 102) | Control group 2 (n = 45) | P value | |
| Chronological age, yr | 8.4 ± 0.5 | 9.4 ± 0.5 | < 0.001* | 11.8 ± 0.6 | 12.6 ± 0.7 | < 0.001* |
| Bone age, yr | 9.9 ± 0.6 | 9.8 ± 0.4 | 0.185 | 12.7 ± 0.4 | 12.7 ± 0.5 | 0.868 |
| Height SDS | 1.0 ± 0.7 | 0.1 ± 1.1 | < 0.001* | 0.7 ± 0.9 | 0.5 ± 1.0 | 0.118 |
| Weight SDS | 0.8 ± 0.9 | 0.2 ± 1.1 | 0.001* | 0.6 ± 0.9 | 0.4 ± 1.0 | 0.111 |
| BMI SDS | 0.4 ± 0.9 | 0.3 ± 1.1 | 0.603 | 0.4 ± 1.0 | 0.3 ± 1.0 | 0.568 |
| AMH, ng/mL | 5.9 ± 3.6 | 5.4 ± 3.7 | 0.419 | 5.1 ± 3.3 | 5.0 ± 3.1 | 0.834 |
| E2, pg/mL | 7.9 ± 1.4 | 5.4 ± 2.0 | < 0.001* | 12.6 ± 15.2 | 14.6 ± 7.8 | 0.504 |
| LH, mIU/mL | 0.4 ± 0.6 | 0.3 ± 0.4 | 0.952 | 4.7 ± 3.5 | 5.7 ± 3.8 | 0.163 |
| FSH, mIU/mL | 3.5 ± 2.5 | 2.3 ± 1.3 | 0.001* | 4.6 ± 1.6 | 5.1 ± 2.0 | 0.176 |
| IGF-I, ng/mL | 278.7 ± 77.4 | 259.8 ± 92.1 | 0.179 | 499.1 ± 148.5 | 465.0 ± 196.4 | 0.375 |
Data are presented as mean ± SD.
GnRH = gonadotropin-releasing hormone, CPP = central precocious puberty, SDS = standard deviation score, BMI = body mass index, AMH = anti-Müllerian hormone, E2 = estradiol, LH = luteinizing hormone, FSH = follicle-stimulating hormone, IGF-I = insulin-like growth factor-I, SD = standard deviation.
*P < 0.05.